However, targeting it safely has remained a challenge since the withdrawal of the anti-obesity drug Rimonabant over serious side effects like depression and anxiety. New research sheds light on a ...

(Kurella M et al. ; published online before print June 8, 2005.) Medscape Medical News, June 13, 2005 Rimonabant in type 2 diabetes Another piece of the rimonabant puzzle fell into place this past ...

This culminated in the approval of Sanofi’s Acomplia (rimonabant) in 2006 for the treatment of obesity, and the large number of clinical trials in non-alcoholic steatohepatitis (NASH), pre ...